Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
12 März 2024 - 9:01PM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company seeking to develop differentiated biologics
for the treatment of atopic dermatitis, chronic obstructive
pulmonary disease, asthma and other inflammatory and immunology
indications (Apogee or the Company), today announced the closing of
its previously announced upsized public offering of 7,790,321
shares of common stock, including the full exercise of the
underwriters’ option to purchase up to 1,016,128 additional shares,
at a public offering price of $62.00 per share. The aggregate gross
proceeds to Apogee from the offering were approximately $483.0
million before deducting underwriting discounts and commissions and
other offering expenses payable by Apogee. All of the shares were
offered by Apogee.
Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD
Cowen and Stifel acted as joint book-running managers for the
offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on March 7, 2024. The offering was made only by means of
a written prospectus. A copy of the final prospectus relating to
the offering may be obtained from: Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; BofA Securities,
NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon,
Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282, by
telephone: (866) 471-2526, by facsimile: (212) 902-9316 or by email
at Prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by telephone at (833)
297-2926, or by email at Prospectus_ECM@cowen.com; or Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, by
telephone at (415) 364-2720, or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company
seeking to develop differentiated biologics for the treatment of
atopic dermatitis (AD), chronic obstructive pulmonary disease
(COPD), asthma and other inflammatory and immunology indications
with high unmet need. Apogee’s antibody programs are designed to
overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering properties to optimize half-life and other
properties. The Company’s two most advanced programs are APG777 and
APG808, which are being initially developed for the treatment of AD
and COPD, respectively. Based on a broad pipeline and depth of
expertise, the company believes it can deliver value and meaningful
benefit to patients underserved by today’s standard of care.
Contacts
Investor Contact:
Noel KurdiVP, Investor RelationsApogee Therapeutics,
Inc.Noel.Kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick1AB dan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
Von Sep 2023 bis Sep 2024